EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators

Navpreet K Hehar, DeGaulle I Chigbu iD

Life · 09.03.2024 · 14 (3) · 361

DOI: 10.3390/life14030361 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 09.03.2024. Verfasst von Navpreet K Hehar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pennsylvania College of Optometry, Salus University, Elkins Park, PA 19027, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vernal keratoconjunctivitis (VKC) is a complex and multifactorial disease process that employs Th2 cell-mediated immunologic processes, which involves the overexpression of interleukin 4 (IL-4), IL-5, IL-9, IL-13, and IL-31, and the activation of mast cells that release IL-5 and CCL-11, recruiting eosinophils to the site of inflammation. The disease primarily affects young males and is more common in regions with warm climates. VKC is characterized by persistent and recurrent conjunctival inflammation that can adversely affect the patient’s quality of life, and, when inadequately treated, may lead to a host of ocular complications, such as corneal shield ulcers and scarring. The major distinct forms of VKC include limbal or palpebral, which may occur in combination. The clinicopathological features of VKC include the presence of pseudogerontoxon, limbal gelatinous hyperplasia, and perilimbal hyperpigmentation. Topical immunomodulators are effective anti-steroidal options for controlling severe and chronic cases of VKC. This review will provide a brief overview of topical immunomodulators, including cyclosporin and tacrolimus, and will highlight the clinical manifestations, pathological mechanisms, and fibroproliferative changes in the conjunctiva that can result from recurrent disease.

Schlagwörter

Stichwörter der Autor:innen

IL-13IL-4IL-5Th2 cellscyclosporine A (CsA)immunomodulatorstacrolimusvernal keratoconjunctivitis

Autor:innen und Institutionen

  • Pennsylvania College of Optometry, Salus University, Elkins Park, PA 19027, USA.

ORCID-Profile: DeGaulle I Chigbu

Zitieren

APA

Hehar, N. K., & Chigbu, D. I. (2024). Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators. Life, 14(3), 361. https://doi.org/10.3390/life14030361

Vancouver

Hehar NK, Chigbu DI. Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators. Life. 2024;14(3):361. doi:10.3390/life14030361

BibTeX
@article{Hehar2024,
  author = {Hehar, Navpreet K and Chigbu, DeGaulle I},
  title = {Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators},
  journal = {Life},
  year = {2024},
  volume = {14},
  number = {3},
  pages = {361},
  doi = {10.3390/life14030361}
}
Kostenlos starten →